Products
BioEngine has developed nearly 100 types of serum-free media for different cell lines, which are suitable for antibodies, vaccines and cell and gene therapy (CGT) fields.
Time:Jun 12,2020
The recognition of technical innovation enterprises is a comprehensive assessment and recognition of enterprises in terms of independent intellectual property rights, the ability to transform scientific and technological achievements, the organizational management level of R&D and innovation, growth indicators, and talent structure. The recognition of BioEngine as a technical innovation enterprise in 2019 marks the full recognition of BioEngine's technology research and development, innovation strength, service level, and operation management, which enhances BioEngine's core competitiveness, improves its brand image, and further stimulates its independent innovation and achievement transformation ability.
Being among the national technical innovation enterprises is another milestone in the development history of BioEngine. In the future, BioEngine will continue to adhere to the business philosophy of "technology-led and service-driven", maintain strong R&D innovation and achievement transformation capabilities, further explore key technologies of animal cell culture, strengthen innovative R&D and application services, and provide sufficient power to promote the development of biopharmaceutical industry.
We have a professional technical team to provide high quality one-stop cell culture service from process development
and optimization, medium formulation design to medium processing and manufacturing for all biopharmaceutical companies.
If you have any question, please click "Quick Message" and leave your message, we will reply to you as soon as possible.
If anything urgent, please call (86)21-68582660-2792.
3F&4F, Building 3, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai, PRC